AJP - Regu AJP: Endocrinology and Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 287: R1434-R1440, 2004. First published August 12, 2004; doi:10.1152/ajpregu.00373.2004
0363-6119/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/6/R1434    most recent
00373.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lortie, M. J.
Right arrow Articles by Munger, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lortie, M. J.
Right arrow Articles by Munger, K. A.

INFLAMMATION AND CYTOKINES

Production of arginine by the kidney is impaired in a model of sepsis: early events following LPS

Mark J. Lortie,1,2,3 Joseph Satriano,1,2,3 Francis B. Gabbai,1,2 Sonia Thareau,3 Ser Khang,1,2 Aihua Deng,1,2 Donald P. Pizzo,3,4 Scott C. Thomson,1,2 Roland C. Blantz,1,2,3 and Karen A. Munger1,2,3

1Division of Nephrology and Hypertension, School of Medicine, and 4Department of Neurosciences, University of California-San Diego, San Diego 92093; 2Veterans Affairs San Diego Healthcare System, and 3Veterans Medical Research Foundation, San Diego, California 92161

Submitted 3 June 2004 ; accepted in final form 5 August 2004

Lipopolysaccharide (LPS) is used experimentally to elicit the innate physiological responses observed in human sepsis. We have previously shown that LPS causes depletion of plasma arginine before inducible nitric oxide synthase (iNOS) activity, indicating that changes in arginine uptake and/or production rather than enhanced consumption are responsible. Because the kidney is the primary source of circulating arginine and renal failure is a hallmark of septicemia, we determined the time course of changes in arginine metabolism and kidney function relative to iNOS expression. LPS given intravenously to anesthetized rats caused a decrease in mean arterial blood pressure after 120 min that coincided with increased plasma nitric oxide end products (NOx) and iNOS expression in lung and liver. Interestingly, impairment of renal function preceded iNOS activity by 30–60 min and occurred in tandem with decreased renal arginine production. The baseline rate of renal arginine production was ~60 µmol·h–1·kg–1, corresponding to an apparent plasma half-life of ~20 min, and decreased by one-half within 60 min of LPS. Calculations based on the systemic production and clearance show that normally only 5% of kidney arginine output is destined to become nitric oxide and that <25% of LPS-impaired renal production was converted to NOx in the first 4 h. In addition, we provide novel observations indicating that the kidney appears refractory to iNOS induction by LPS because no discernible enhancement of renal NOx production occurred within 4 h, and iNOS expression in the kidney was muted compared with that in liver or lung. These studies demonstrate that the major factor responsible for the rapid decrease in extracellular arginine content following LPS is impaired production by the kidney, a phenomenon that appears linked to reduced renal perfusion.

inducible nitric oxide synthase; sepsis; lipopolysaccharide; ornithine



Address for reprint requests and other correspondence: M. J. Lortie, Division of Nephrology and Hypertension, UCSD School of Medicine, 3350 La Jolla Village Dr., San Diego, CA 92161 (E-mail: mlortie{at}ucsd.edu)




This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
M. A. Arndt, V. Battaglia, E. Parisi, M. J. Lortie, M. Isome, C. Baskerville, D. P. Pizzo, R. Ientile, S. Colombatto, A. Toninello, et al.
The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis
Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1411 - C1419.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. Satriano, R. Cunard, O. W. Peterson, T. Dousa, F. B. Gabbai, and R. C. Blantz
Effects on kidney filtration rate by agmatine requires activation of ryanodine channels for nitric oxide generation
Am J Physiol Renal Physiol, April 1, 2008; 294(4): F795 - F800.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. A. Munger, R. C. Blantz, and M. J. Lortie
Acute renal response to LPS: impaired arginine production and inducible nitric oxide synthase activity
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R684 - R691.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.